Survival comparison of HER2 breast cancer patients according to HR status: analysis of a single Portuguese centredoi:10.1016/S0960-9776(21)00201-0G. Nogueira-CostaJ. GramaaI. FernandesC. TrabuloJ. GonalvesI. PinaThe Breast
Conclusion: It could be shown that, compared to historical controls, targeted therapy against HER2 prolongs overall survival of patients with HER2-positive metastatic breast cancer who receive treatment in routine care.doi:10.5539/cco.v2n1p17Rudolf Weide...
Relative Breast Cancer Survival Rate by Age 11 min read If you’ve been diagnosed withbreast cancer, your focus will be on getting the right treatment, but you’ll wonder, too, about your chances of surviving. Your doctor may call this your prognosis. It’s an estimate of how the disease...
- 《Breast Care》 被引量: 65发表: 2013年 Pertuzumab: In the First-Line Treatment of HER2-Positive Metastatic Breast Cancer The humanized monoclonal antibody pertuzumab is the first in a new class of drugs, the human epidermal growth factor receptor (HER) dimerization inhibitors... Keating,M ...
Abstract P6-10-12: Metformin increases survival in hormone receptor-positive, Her2-positive breast cancer patients with diabetes INTRODUCTION: Metformin use has recently been observed to decrease both the rate and mortality of breast cancer. Our study was aim to determine whether metformin use is ass...
Data were collected from 62 patients who were initially diagnosed with breast cancer that had metastasized to the brain. The ER, PR and HER2 status of the samples from the primary tumors and the brain metastases was determined. Differences in the immunohistochemical profiles of ER, PR or HER2 ...
ER, PR, and HER2 are routinely available in breast cancer specimens. The purpose of this study is to contrast breast cancer-specific survival for the eight ER/PR/HER2 subtypes with survival of an immunohistochemical surrogate for the molecular subtype based on the ER/PR/HER2 subtypes and tumor...
According to international guidelines, endocrine therapy (ET) is the preferred option for hormone receptor-positive (HR+) HER2-negative (HER2−) metastatic breast cancer. In spite of clear recommendations, these are not strictly followed in daily pract
SPSS (v15) was used to plot Kaplan–Meier survival curves using breast cancer-specific death as an outcome endpoint (log-rank testing). Cox regression analysis was carried out to evaluate the independence of HER2 in predicting the outcome in conjunction with age, oestrogen receptor (ER), grade...
Intratumoral human epidermal growth factor receptor 2 (HER2) heterogeneity has been reported in 16–36% of HER2-positive breast cancer and its clinical impact is under discussion. We examined the biological effects of HER2-heterogeneity on mouse models and analyzed metastatic brains by RNA sequence ...